Page last updated: 2024-10-31

moxisylyte and Multiple Sclerosis

moxisylyte has been researched along with Multiple Sclerosis in 1 studies

Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)

Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yuill, GM1
Neary, D1

Other Studies

1 other study available for moxisylyte and Multiple Sclerosis

ArticleYear
Letter: Thymoxamine ineffective against spasticity.
    Lancet (London, England), 1973, Dec-29, Volume: 2, Issue:7844

    Topics: Administration, Oral; Drug Evaluation; Humans; Moxisylyte; Multiple Sclerosis; Myotonia; Spasm; Spon

1973